Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120791 | 0.90 | KMT2A (0.38) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL2340622 | 0.90 | KMT2A (0.38) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL142219 | 0.88 | MEN1 (0.39) | KMT2AMEN1MAPK1GHSRGAA | |
| SCHEMBL387928 | 0.85 | KMT2A (0.39) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL3955815 | 0.85 | KMT2A (0.54) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL76966 | 0.84 | BTK (0.38) | KMT2AMEN1MAPK1GHSRGAA | |
| SCHEMBL202837 | 0.84 | BTK (0.38) | KMT2AMEN1MAPK1GHSRGAA | |
| Hydrochloric Acid SCHEMBL26121308 | 0.84 | KMT2A (0.38) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL1012064 | 0.83 | FAAH (0.39) | KMT2AMEN1MAPK1GHSRGAA | |
| SCHEMBL8980908 | 0.83 | FAAH (0.39) | KMT2AMEN1MAPK1GHSRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| CN-120078781-A | Application of BET/AKT double-pathway active dihydroquinazolinone compound in preparation of anti-prostate cancer drugs | 烟台大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-120058710-A | Dihydroquinazolinone compounds and methods of making the same | 烟台大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4362989-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Limited (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| CN-1503790-A | Heterocyclic sulfonamide inhibitors of beta amyloid production | — | 2004-06-09 | — | — | CN | disclosed |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | MCLAUGHLIN MARK L (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1341779-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2003-09-10 | — | — | EP | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| US-6566334-B1 | For therapy of bacterial infection | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-05-20 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002057252-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-1999065881-A1 | HETEROCYCLIC COMPOUNDS AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | KMT2A 1343/4885KDM4E 1852/4885MEN1 613/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | KMT2A 1343/4885KDM4E 1852/4885MEN1 613/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | KMT2A 1052/4885KDM4E 671/4885MEN1 4664/4885 |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | VIP, MDK, HM13 | KMT2A 4497/4885KDM4E 4672/4885MEN1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.